GERD Device Maker’s Experience Exemplifies Coverage Barriers For Small Biz
This article was originally published in The Gray Sheet
Executive Summary
Curon Medical's five-year battle to surpass 10% of U.S. public and private insurer coverage of its Stretta GERD therapy underscores the difficulties small companies face in navigating the reimbursement process
You may also be interested in...
Analyst Conferences In Brief
Stryker: Corin's Cormet hip resurfacing device will be sold by Stryker in the U.S. under a deal struck with the British orthopedic firm, Stryker CFO Dean Bergy said Sept. 8 at the Thomas Weisel Healthcare Tailwinds Conference in Boston. "It's very clear that hip resurfacing has been very well received in many European markets, Australia and Canada. I don't know that the opportunity will be as great in the U.S., but we felt like we'd have to be on the forefront of this technology," Bergy said. Stryker will purchase the hips from Corin on a transfer price basis. Corin has already submitted a PMA application to FDA for the device. If approved, the device will likely compete against Smith & Nephew's Birmingham Hip Resurfacing device, which garnered a positive recommendation from FDA's Orthopaedic & Rehabilitation Devices Panel Sept. 8 in Gaithersburg, Md....
Analyst Conferences In Brief
Stryker: Corin's Cormet hip resurfacing device will be sold by Stryker in the U.S. under a deal struck with the British orthopedic firm, Stryker CFO Dean Bergy said Sept. 8 at the Thomas Weisel Healthcare Tailwinds Conference in Boston. "It's very clear that hip resurfacing has been very well received in many European markets, Australia and Canada. I don't know that the opportunity will be as great in the U.S., but we felt like we'd have to be on the forefront of this technology," Bergy said. Stryker will purchase the hips from Corin on a transfer price basis. Corin has already submitted a PMA application to FDA for the device. If approved, the device will likely compete against Smith & Nephew's Birmingham Hip Resurfacing device, which garnered a positive recommendation from FDA's Orthopaedic & Rehabilitation Devices Panel Sept. 8 in Gaithersburg, Md....
Curon Stretta GERD Coverage Boost In 2005 Has Sales Force Salivating
Curon Medical hopes to quintuple the reimbursement-eligible patient population for its minimally-invasive Stretta gastroesophogeal reflux disease (GERD) treatment by mid-2005